Sydney, June 19, 2026, 06:05 (AEST)
- Cochlear finished at A$114.29, gaining 2.67%. Volume came in at roughly 798,000 shares.
- The gain came as the S&P/ASX 200 dropped 0.62%. Australia’s healthcare sector put on 0.35%.
- UBS has trimmed its FY26-FY27 earnings estimates by 2%-3% and dropped its price target to A$106 from A$109, sticking with its Neutral rating.
Cochlear Limited stock finished Thursday up 2.7% at A$114.29, tacking on A$2.97 for the day. The hearing-implant company extended its rebound even as the broader Australian market declined. The stock closed before this report’s deadline and will start Friday’s trade at that level.
Cochlear is up 11.1% in the past week and nearly 27% since its April 29 low at A$90. But the stock is still down 64.2% from its July peak of A$319.42. Investors are starting to look past the shock—though not fully.
Valuation is getting tighter. Morningstar strategist Lochlan Halloway said on June 5 that the shares are “slightly undervalued” and kept his A$110 fair-value estimate. The stock finished Thursday above that level. Halloway sees rollout issues with Cochlear’s Nexa implant system easing and still figures the company holds around 60% of the global market. Morningstar
Cochlear bounced after its April 22 profit warning. The company slashed its FY26 underlying net profit outlook to A$290 million-A$330 million from A$435 million-A$460 million. Shares tumbled 40.7% to A$99.58, marking their biggest one-day drop ever.
Cochlear is pointing to hospital capacity issues, low referrals from hearing-aid providers and weak U.S. consumer sentiment for its problems. In Europe, the company is seeing a backlog of surgeries and strikes. CEO Dig Howitt said, “We remain confident of our market leadership,” and pointed to strong Nexa uptake. Cochlear expects second-half sales to increase 2%-6% in constant currency, but it also warned about possible receivables provisions, restructuring charges and the impact of a stronger Australian dollar. ASX Announcements
Gulf conflict continues to drag on earnings. Cochlear has warned about order cancellations, shipment delays and a rise in unpaid bills, Reuters reported in a June 17 update. The company also pointed to slower surgeries and weaker referral rates in developed markets.
Competition is also weighing. Jarden’s Steve Wheen said MED-EL and Advanced Bionics have picked up share while Cochlear tried to push pricing higher in the U.S. He said the “price premium is not sticking” as reimbursement hasn’t moved up. Wilson Asset Management
The run-up looks shaky if U.S. referrals and European surgery numbers don’t bounce back, or if Middle East buyers hold off on more orders and payments. Another cut to earnings would put fresh pressure on a valuation that’s now above Morningstar’s estimate and the UBS target.
Thursday’s gain looks like a valuation reset, not a clear sign that earnings have turned. For a real rerating, investors want to see stronger referral flows, hospitals working through surgery backlogs and Nexa sticking to its price against competitors. At this stage, the shares are rebounding faster than the earnings story.
